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Abstract
Optic neuritis has been described among the
toxic effects of Ethambutol. This side effect is dose
related. The mean duration of Ethambutol induced optic
neuritis (EON) is three months. We report a case of
EON after few days of exposure to Ethambutol and the
symptoms resolved after discontinuation of Ethambutol.
This most likely represents an idiosyncratic reaction
which is different as compared to dose related optic
neuritis.
Introduction
Ethambutol gained  acceptance in tuberculosis ther-
apy because of improved patient tolerance and convenience
of administration and has been used in the treatment of
tuberculosis for more than 25 years.1 It acts only on prolif-
erating cells, apparently by interfering with the synthesis of
RNA by inhibiting the incorporation of mycolic acid into
the mycobacterial cell wall.2 The most important side effect
of this drug is optic neuritis, resulting in decreased visual
acuity and colour blindness. This reaction is proportional
to the dose of ethambutol and is observed in 15% of
patients receiving 50 mg per kg per day, in 5% of
patients receiving 25 mg per kg per day and in less then
1% of patients receiving daily doses of 15 mg per kg.3
These symptoms usually develop after few weeks of
treatment. We report a patient who developed bilateral
optic neuritis on day three of ethambutol therapy.
Possible mechanism of optic nerve injury is discussed. 
Case Report 
A 35-year-old female presented to the emergency
room with the history of intermittent fever for one
month, altered mental status and left eyelid drooping for
a day. Her neurological examination showed anisocoric
pupils, left partial ptosis and left abducent nerve palsy.
Visual acuity in both eyes was normal. Neck stiffness
and Kerning's sign were positive. MRI brain revealed
multiple ring enhancing lesions involving the supra and
infratentorial brain compartment and diffuse meningeal
enhancement. CSF analysis showed glucose=10 mg/dL;
protein=161 mg/dL; pleocytosis=618 cells with lympho-
cytic predominance (80%). A diagnosis of tuberculous
meningitis was suggested. A CSF culture was later
reported positive for AFB. She was started on rifampicin
10 mg/kg, isoniazid 5 mg/kg, ethambutol 25 mg/kg and
pyrizinamide 30 mg/kg of body weight per day, along
with pyridoxine 50 mg daily. She was also started on
adjuvant therapy with Prednisolone 30 mg twice daily.
She returned after three days with complaints of pro-
gressive visual loss. Neurological examination revealed
visual acuity of 20/400 on the right and 20/200 on the
left. Visual Evoked Potentials, using checkerboard pat-
tern stimulation showed bilateral optic pathway dys-
function (P100 latencies of 140 and 146 on the right and
left side respectively). Ethambutol was discontinued and
streptomycin was started. Her visual acuity improved to
20/40 on the right and 20/20 on the left after one month
of follow up.
Discussion 
Ethambutol induced optic neuritis (EON) is well
documented. A survey of 37 ethambutol toxicity cases
reported in the Danish Board of Adverse Reactions
showed preponderance in the elderly and females, count-
ing to 1% of patients receiving ATT.4 In one study, 13
patients developed optic neuritis between 1 to 6 (mean =
2.9) months after  receiving ethambutol at a dose rang-
ing from 13 to 20 mg/kg/day (mean=17 mg/kg/day) for
pulmonary tuberculosis  or of the lymph nodes.5 Choi et
al reported ethambutol toxicity at a dose as low as 12.3
mg/kg6, while others have reported over
20 mg/kg/day after 3 weeks to 15 months.2 As in this
case reported, changes in visual acuity, visual field, fun-
dal appearance and colour sensation have been reported
with EON in other studies.2,5 The occasionally observed
reddish optic disc, retinal hemorrhages, a very fine gran-
ular pigment alteration of the macular region and loss of
vision for more than a year without optic disc pallor sug-
gests a toxic retinitis or retinoneuritis rather than neuri-
tis.3 However in our patient, slit lamp examination
revealed normal anterior chamber and optic disc hyper-
emia with mild disc edema bilaterally.
EON has been reported to be reversible after
withdrawal of the drug; however severe damage can lead
to irreversible visual loss. Out of 13 patients at Siriraj
Hospital, 54% experienced visual recovery after stop-
ping the drug.5 In a series of seven consecutive patients7
with severe visual deficit due to ethambutol toxicity,
only 42.2% achieved a visual recovery of 20/200 on a
follow-up of 8.3 + 2.1 months after stopping the drug.
On fluorescein angiography, three cases (42.2%) pro-
gressed to optic atrophy during the follow-up with per-
manent visual damage. There was no predisposing or
risk factors contributing toward the visual loss.7
However the association of old age with irreversible
visual loss has been considered. 
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The pathogenic mechanism underlying EON is
controversial. Data from animal models showed that in
doses of 105 to 2500 mg/kg per day for 18 to 102 days,
16% albino rats developed bilateral lesions consisting of
focal axonal swelling without demyelination, in optic
chiasma and the intracranial portions of optic nerves.9
Retinal toxicity has also been implicated as a mechanism
of Ethambutol damage. The toxicity of ethambutol and
related agents was evaluated in rodent retinal dissociat-
ed cell preparations and whole eyes. Calcium fluxes and
mitochondrial function were evaluated by fluorescent
and staining techniques. For in vivo assays, adult rats
were administered oral ethambutol over a 3-month peri-
od. Cell survival was assessed by stereology.
Ethambutol is specifically toxic to retinal ganglion cells
in vitro and vivo both. Endogenous glutamate is neces-
sary for the full expression of ethambutol toxicity, and
glutamate antagonists prevent ethambutol-mediated cell
loss. Ethambutol causes a decrease in cytosolic calcium,
an increase in mitochondrial calcium, and an increase in
the mitochondrial membrane potential. The visual loss
associated with ethambutol may be mediated through an
excitotoxic pathway, so that ganglion cells are rendered
sensitive to normally tolerated levels of extracellular
glutamate. Ethambutol perturbs mitochondrial function.
Its toxicity may depend on decreased ATPase activity
and mitochondrial energy homeostasis. Glutamate
antagonists may be useful in limiting the side effects
seen with ethambutol.10
As ethambutol toxicity is dose related, rapid
development of optic neuritis in our patients is most likely
related to an idiosyncratic reaction to drug. Karnik et al
reported rapidly progressive deterioration of vision after
only three days of treatment with ethambutol.11 In conclu-
sion, ethambutol could cause an optic neuritis after a few
doses. Mechanism of injury is probably different from the
common optic neuritis secondary to ethambutol. Early
detection of these cases and withdrawal of ethambutol may
be associated with good recovery.
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